Pharma Focus Europe

RevOpsis and Kemwell Biopharma Establish Partnership to Accelerate the Development of Innovative Multispecific Biologics

Tuesday, June 18, 2024

RevOpsis Therapeutics, a pioneering biopharmaceutical company focused on multispecific ophthalmic therapies, and Kemwell Biopharma, a top-tier contract development and manufacturing organization (CDMO) in the biologics field, have entered into a strategic partnership. This collaboration aims to accelerate the development of RevOpsis' flagship candidate, RO-104, a novel tri-specific biologic for treating neovascular age-related macular degeneration (nAMD).

Kemwell will handle the production of RO-104, which targets three primary angiogenic pathways (VEGF-A, VEGF-C, Ang-2) to treat nAMD, a leading cause of blindness worldwide. RO-104's unique ability to engage these pathways simultaneously establishes it as a first-in-class, fully human monotherapy biologic, poised to revolutionize the treatment of retinal vascular diseases.

Kemwell's facility in India, the first to comply with commercial current Good Manufacturing Practices (cGMP), is renowned for its expertise in complex protein manufacturing. This partnership combines Kemwell's manufacturing capabilities with RevOpsis' advanced Rev-Mod platform to expedite the development of new multispecific biologics.

"Partnering with Kemwell is a significant step in advancing our lead candidate, RO-104, and our pipeline of innovative multispecific biologics," said Ram Bhandari, MD, Co-founder and Interim CEO of RevOpsis. "Kemwell's excellent reputation in biologics manufacturing, paired with our proprietary Rev-Mod platform, ensures that we can efficiently bring transformative therapies to patients. This collaboration supports our mission to rapidly develop groundbreaking treatments and make our innovations accessible to patients globally."

Kemwell Biopharma, added, "We are thrilled to work with RevOpsis on manufacturing and commercializing RO-104. Our skills in complex protein manufacturing, along with RevOpsis' innovative therapeutic approaches, hold great potential for advancing treatments for retinal vascular diseases. This partnership underscores our commitment to delivering high-quality biologics to patients who need them."

This collaboration will allow RevOpsis to efficiently move from pre-clinical research to first-in-human clinical trials, speeding up the development of RO-104 and enhancing the overall platform. By integrating RevOpsis' next-generation modular multispecific biologics platform with Kemwell's extensive expertise in biologics development and manufacturing, this partnership aims to hasten the journey from therapeutic discovery to Investigational New Drug (IND) submission. The collaboration will simplify processes from preclinical activities to clinical manufacturing, significantly reducing the complexity and timelines associated with early GMP manufacturing.

RO-104 is RevOpsis' leading candidate, developed using the proprietary Rev-Mod platform. It is a first-in-class, fully human modular tri-specific biologic designed to address all three clinically validated major angiogenic pathways (VEGF-A, VEGF-C, Ang-2) involved in the progression of retinal vascular diseases like nAMD. RO-104 represents a significant advancement in the treatment of these conditions, supported by substantial preclinical evidence demonstrating its efficacy and safety in established animal models.

The Rev-Mod Platform uses a modular 'plug-and-play' approach to facilitate the discovery and development of multispecific biologics that target a wide range of chronic, prevalent diseases. This platform features a vast library of nearly 30 billion fully human antibody components in a structured phage display system, enabling the rapid identification and assembly of multispecific product candidates. The Rev-Mod platform's compatibility allows for the swift design of biologics to address unmet needs in key therapeutic areas, including ophthalmology, oncology, and immune-mediated diseases.

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva